Open Access

Genome-wide analysis of copy number variations identifies PARK2 as a candidate gene for autism spectrum disorder

  • Chia-Lin Yin1, 2,
  • Hsin-I Chen1,
  • Ling-Hui Li3,
  • Yi-Ling Chien1,
  • Hsiao-Mei Liao1, 4,
  • Miao Chun Chou5,
  • Wen-Jiun Chou5,
  • Wen-Che Tsai1,
  • Yen-Nan Chiu1,
  • Yu-Yu Wu6,
  • Chen-Zen Lo3,
  • Jer-Yuarn Wu3,
  • Yuan-Tsong Chen3 and
  • Susan Shur-Fen Gau1Email author
Contributed equally
Molecular AutismBrain, Cognition and Behavior20167:23

https://doi.org/10.1186/s13229-016-0087-7

Received: 29 October 2015

Accepted: 22 March 2016

Published: 1 April 2016

Abstract

Background

Autism spectrum disorder (ASD) is an early-onset neurodevelopmental disorder with complex genetic underpinning in its etiology. Copy number variations (CNVs) as one of the genetic factors associated with ASD have been addressed in recent genome-wide association studies (GWAS). However, the significance of CNV has not been well investigated in non-Caucasian ASD population.

Methods

To identify the pathogenic CNVs responsible for ASD in Han Chinese, we performed a segment-based GWAS of CNV in 335 ASD cases and 1093 healthy controls using Affymetrix single nucleotide polymorphism (SNP) array by focusing on case-specific CNVs. PARK2 was one of the important genes with several case-specific regions overlapped on it. The findings were validated in the initial screen sample set and replicated in another sample set by real-time quantitative PCR (qPCR).

Results

A total of six CNVs at 6q26 that spanned different exons of PARK2 were identified. The PARK2 expression level was down-regulated at exon-dependent manner in cases with either deletion or duplication. The result revealed that the gene function might be disrupted by exonic deletion and duplication. We also observed that the ASD case with exonic duplication demonstrated a more severe interference of PARK2 expression and the clinical feature than the ones with deletion at the exons 2–4 of the PARK2 gene.

Conclusions

Our finding provides evidence to support that CNVs affecting PARK2 function might contribute to genetic etiology of a proportion of cases with ASD. The intriguing results of this work warrant further study on characterizing the functional impact of various exonic CNVs on the PARK2 gene.

Trial registration

ClinicalTrials.gov NCT00494754

Keywords

PARK2 Autism spectrum disorder (ASD) Copy number variations (CNVs) Family study Gene expression

Background

Autism spectrum disorder (ASD) is a common, early-onset, long-term impairing neurodevelopmental disorder with complex genetic underpinning in its etiology [1, 2]. Recent massive improvement in cytogenetic analysis enhanced the resolution and accuracy in detecting genomic structural changes. Copy number variations (CNVs) are the submicroscopic chromosomal deletions or duplications that affect more than 1000 base pairs of deoxyribonucleic acid (DNA) sequence and alter normal gene expression either by removing or adding the copies of a gene or multiple genes [3, 4]. Accumulated evidence from genome-wide CNV studies showed that ASD patients carried higher CNV burden than healthy controls [5], and up to 10–20 % of ASD cases carried one or more CNVs that contribute to the phenotypes [6].

Evidence from several studies of genome-wide analyses of CNVs supports that rare CNVs, either de novo or inherited, are associated with ASD [79]. Sebat et al.’s report of rare de novo CNVs in ASD using array comparative genomic hybridization (aCGH) method [7] was supported by a large-scale CNV study implemented by the Autism Genome Project (AGP) showing that the difference was mainly contributed by the deletion-type CNVs [8]. Sander et al. reported that duplications of 7q11.23, the region of Williams Syndrome, were strongly associated with ASD and that large de novo CNVs encompassing multiple genes were more pathogenic in ASD (OR = 5.6, CI = 2.6–12.0, P = 2.4 × 10−7) [9]. Many of these loci/genes are relevant to the process of neurotransmission [1012], synapse formation [10, 11], or protein ubiquitination [12]. Functional levels of genes change with CNV (termed dosage sensors) may additionally contribute to the etiology of ASD [1012].

The PARK2 gene (OMIM*602544) is one of neurodevelopmental genes that was originally discovered as one of the causes of early-onset Parkinson disease (PD) [13] and was subsequently reported to be associated with schizophrenia [14], ASD [15], and attention-deficit/hyperactivity disorder (ADHD) [16]. Glessner et al. (2009) identified deletions in the PARK2 gene in seven ASD patients, but none in controls (P = 0.0047) [15]. Scheuerle et al. then found two ASD patients with deletion and duplication of PARK2 [17], and suggested that distinct phenotype in patients might be due to different CNV types in PARK2 and the duplications may be equally causative for ASD [17]. Overall, these two studies provide some evidences to support PARK2 as a pathogenic gene of ASD [15, 17].

The majority of population-based studies of genome-wide CNVs are about European ancestry but there is no such study in the Asian population. Therefore, it is of great importance to discover candidate CNVs that are responsible for ASD in Han Chinese. With the identification of pathogenic CNVs, clinical diagnosis, and treatment for ASD should be largely improved. Here, we report the study using genome-wide association analysis of CNVs in 335 ASD cases and 1093 healthy controls of Han Chinese ancestry in Taiwan. We identified a marginally significant (not adjusted for multiple testing) ASD-associated gene, PARK2, which was co-localized with a CNV region specific to ASD. The finding was further replicated in an independent sample set of 301 ASD cases and 301 healthy controls. We also investigated how the expression of the PARK2 gene was affected by the intragenic CNVs covering various exons. Finally, we linked the clinical features of ASD to the PARK2 CNVs and proposed the possible pathogenic effect of various exonic CNVs of PARK2.

Methods

Participants

ASD cohort

A total of 335 Han Chinese patients with ASD, aged 9.39 ± 4.04 years (male 89.3 %) were recruited in Taiwan for the genome-wide CNV comparison. They were clinically diagnosed with autistic disorder according to the DSM-IV and confirmed by using the Chinese version of the Autism Diagnostic Interview-Revised (ADI-R) [18]. The ADI-R interviews revealed the 335 probands scored 20.43 ± 6.12 in the “qualitative abnormalities in reciprocal social interaction” (cut-off = 10), 14.75 ± 4.32 in the “qualitative abnormalities in communication, verbal” (cut-off = 8), and 6.95 ± 2.47 in the “restricted, repetitive and stereotyped patterns of behaviors” (cut-off = 3) currently if ages of 5 or younger or at their age of 4 to 5 years old with the typical symptoms if older than 5 years old (Table 2). They were recruited from Department of Psychiatry of National Taiwan University Hospital (NTUH), Chang Gung Memorial Hospital (CGMH), Taoyuan, and Taoyuan Mental Hospital (TMH), Taiwan. The patients diagnosed as fragile X, Rett’s disorder, or other known chromosome/genetic disorders were excluded from the study [19]. Their parents also reported about the patients’ autistic behaviors on the Social Responsiveness Scale (SRS) [18], and the cognitive functions assessed by the Weschler Intelligence Scale for Children-3rd edition (WISC-III) and Wisconsin Card Sorting Test (WCST). The detailed description of the current and past ADI-R, SRS, WISC-III, and WCST is provided in Table 2.

Healthy control cohort

One thousand ninety-three individuals (aged 68.07 ± 10.12 years, male 48.0 %) from the Han Chinese Cell and Genome Bank (HCCGB) in Taiwan served as controls in the CNV screening stage [20]. This control cohort received physical check-up and questionnaire screening to confirm that they did not have any physical condition.

The sample for replication

The ASD cohort for replication consisted of 301 independent patients (aged 11.25 ± 5.47 years, male 88.4 %) recruited from the same places as the initial ASD cohort and received the same assessments. The ADI-R interviews revealed that the 301 probands for replication scored 20.77 ± 6.28 in the “qualitative abnormalities in reciprocal social interaction” (cut-off = 10), 15.87 ± 4.63 in the “qualitative abnormalities in communication, verbal” (cut-off = 8), and 7.29 ± 2.65 in the “restricted, repetitive and stereotyped patterns of behaviors” (cut-off = 3) currently if ages of 5 or younger or at their age of 4 to 5 years old with the typical symptoms if older than 5 years old (Table 2). The healthy controls for replication included 301 unrelated individuals (controls aged 19.59 ± 8.90 years, male 64.1 %) recruited at NTUH, Taipei, Taiwan, either by teachers’ referral or advertisement. Their lifetime and current mental status were clinically evaluated by the corresponding author and confirmed by psychiatric interviews. Their family history of mental disorders was also screened by clinical interviews.

The study protocol was approved by the Research Ethics Committee at each participating hospital and Academia Sinica (National Taiwan University Hospital, 9561709027; Chang Gung Memorial Hospital-Linkou, 93-6244; Taoyaun Psychiatric Center, Ministry of Health and Welfare, C20060905; Kaohsiung Chang Gung Memorial Hospital, 99-1548A3; Academia Sinica, AS-IBMS-MREC-91-10). Written informed consent was obtained from the parents and participants after the purposes and procedures of the study were explained, and the voluntary participation was assured.

Genome-wide SNP genotyping and data analysis

Genomic DNA was extracted from the peripheral blood of the ASD subjects and from EBV-transformed B cells of the healthy controls by PUREGENE Genomic DNA Purification Kit (Qiagen, Valencia, CA). The DNA samples were subjected to genotyping using Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA) according to the manufacturer’s instructions and performed in the National Center for Genome Medicine at Academia Sinica, Taipei, Taiwan (http://ncgm.sinica.edu.tw/ncgm_02/index.html). The hybridization intensities were captured by GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA). CNVs were called using Affymetrix Genotyping Console software v.4.1 (Affymetrix, Santa Clara, CA). Genes overlapped with the CNV regions were reported according to UCSC genes (NCBI37/hg19). Details on genotyping and sample quality control, the procedures for CNV detection and extraction, and the global CNV burden measurement are provided in Additional file 1: Figure S1 and Additional file 1: Table S1.

Case-specific CNV locus

The segment-based association analysis was conducted using Python (https://www.python.org). CNV regions on autosomes were analyzed in all samples while CNV regions on sex chromosomes were analyzed in male samples only. Duplication-type CNV and deletion-type CNV were treated as different CNVs. CNV regions identified in each individual were stacked and partitioned at each unique start and stop site for the CNV regions to form non-overlapping genomic segments for frequency calculation. A total of 38,660 individual autosomal CNV regions formed 7883 CNV segments, and a total of 1999 individual sex-chromosome CNV regions identified in male samples formed 615 CNV segments. CNV segments that were detected only in cases were defined as case-specific CNVs. The case-specific CNV segments that were flanking to each other or belonged to the same gene were manually merged into case-specific CNV loci for report.

Validation and replication analysis of CNVs

The case-specific CNVs were validated by SYBR-Green based genomic quantitative PCR (qPCR) using ABI StepOne Plus system (Applied Biosystems, Forster, CA). Primer pairs specific to various exons of the PARK2 gene (NM_004562), the FARP2 locus on chromosome 2 and the GAPDH locus on chromosome 12 were used as internal controls for qPCR. A total of 10 ng of genomic DNA was used in each PCR reaction, which was conducted in triplicate for both target locus and internal control loci. The fold change of copy number was calculated by comparative Ct method. The relative fold change to normal subject was determined as 2−∆∆Ct. Samples with fold change greater than 1.25 (duplication) or less than 0.75 (deletion) are considered to have a copy number change.

At replication stage three additional pairs of primers were designed to cover exons 1, 2, and 4 of the PARK2 gene, respectively. The information of these primers is listed in Additional file 1: Table S2.

Gene expression analysis

Total ribonucleic acid (RNA) was extracted from peripheral blood cells by RNeasy Miniprep Kit (Qiagen system) following the manufacturer’s instructions. Of purified RNA sample, 1.2 μg was used for complementary DNA (cDNA) synthesis by using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The cDNA product was subjected to SYBR-Green based qPCR by ABI StepOne Plus system (Applied Biosystems) for PARK2 expression analysis. GAPDH was used as an internal control. A 20-fold dilution of cDNA product was used in each PCR reaction in triplicate for both target gene and internal control gene. The information of the primers is listed in Additional file 1: Table S2. The probands, PARK2 CNV carriers in the families, non-carriers in the families, and four unrelated controls without PARK2 CNV were assayed individually. Relative fold change of PARK2 exon expression was calculated by 2−∆∆Ct method using individuals without PARK2 CNV as expression baseline.

Statistical analysis

Two-tailed Fisher’s exact test was performed to evaluate the associations of individual CNV segments and case-specific CNV loci with ASD. Student t test was used to compare the messenger ribonucleic acid (mRNA) expression level between the two groups.

Results and discussion

Case-specific CNV loci

The present study focused on the case-specific CNV segments, which were detected in at least one case but none in healthy controls from the screening stage (Additional file 1: Figure S2). The flanking case-specific CNV segments with the same type of CNV were merged into CNV loci for statistical analysis and annotation. A total of 461 case-specific CNV loci overlapped with genes were identified (Additional file 1: Table S3). These case-specific CNV loci consisted of 196 deletions (42.5 %) and 265 duplications (57.5 %), and most of them were individually rare (<1 % of cases). These CNV loci spanned 0.3 to 4623.3 kb (average CNV locus size: 143 kb) and overlapped with exons of a single gene to more than 40 genes.

Among the identified case-specific CNV loci, 17 were located in six chromosomal regions of the well-known ASD-associated CNV, 1q21.1, 15q11.2-13.1, 15q13.3, 16p11.2, 22q11.21, and 22q13.33 (Additional file 1: Table S4). Our findings that there were case-specific CNVs located in these 17 ASD-associated loci replicate those findings of pathogenic CNV loci from previous studies [5, 79, 15, 2124]. In addition to the known CNV loci associated with ASD, we identified 17 marginally significant (not adjusted for multiple testing) case-specific CNV loci at which duplication and deletion were detected in at least four cases (patient frequency (F patient) > 1 %; P < 0.01) (Table 1). Genes overlapped with these case-specific CNV loci could be candidate pathogenic genes for ASD (Table 1). Among them, the PARK2 gene is the only one that has been reported to be associated with ASD.
Table 1

Selected case-specific copy number variation loci

Locus

Position (start–end)

Gene

Gain_case

Loss_case

Gain_control

Loss_control

1p36.21

13377035–13538299

PRAMEF8,PRAMEF9,PRAMEF13,PRAMEF19,PRAMEF16,PRAMEF20

6

0

0

0

1p36.13

17262235–17295200

CROCC

4

0

0

0

1q25.1

174802140–174802829

RABGAP1L

0

4

0

0

2p11.2-p11.1

91801473–92136779

LOC654342,Mir_544,GGT8P,ACTR3BP2

7

0

0

0

3p12.3

75639495–75930920

MIR1324,FLJ20518,LOC401074,ZNF717,MIR4273

10

0

0

0

3q22.1

129806912–129914958

ALG1L2, FAM86HP

27

1

0

0

4p16.1

9486075–9744591

MIR548I2,AB059369

8

1

0

0

4p16.3

3885796–4190560

DQ584669,FAM86EP,BC042823,OTOP1

14

0

0

0

4q13.2

69371991–69410211

UGT2B15, UGT2B17

0

5

0

0

6q26

162187125–162680305

PARK2

1

3

2

0

8p23.1

12542721–12587390

LONRF1,MIR3926-1,MIR3926-2

5

0

0

0

9q13

68176154–68683835

AK308561,BC080605,LOC642236

17

0

0

0

12p13.31

8378239–8536600

LINC00937, FAM86FP, FAM90A1

5

0

0

0

14q11.2

24429298–24513905

DHRS4,DHRS4L2,DHRS4L1

1

11

5

10

19q13.42

55360538–56717229

>60 genes

4

0

0

0

21q11.2

14456404–14594223

ANKRD30BP2

8

1

0

0

22q11.23

24396802–24404830

GSTTP2

0

4

0

0

Validation and replication analysis of CNVs at the PARK2 locus

A total of four exonic CNVs within the PARK2 locus were identified in ASD cohort at the initial screening stage (three deletions, one duplication, F patient = 1.19 %). Each of them overlapped with different parts of the PARK2 gene and was categorized into three coverage regions: A, B, and C (Fig. 1). With the three regions as baits, two duplications within the A region were identified in two healthy controls (F control = 0.18 %) (Fig. 1). Nevertheless, both of them were shorter, and only one overlapped with the exon 3 of PARK2. The prevalence of CNVs at the entire PARK2 locus remained significant in ASD cases compared to the controls (P = 0.030). Copy number status at the PARK2 locus in the initial samples was validated by genomic qPCR (Fig. 2a and Additional file 1: Figures S3 and S4).
Fig. 1

Genomic location of CNVs at the PARK2 locus. Red bars and dark blue bars represent deletions and duplication, respectively, at the PARK2 gene detected in the cases. Light blue bars represent duplication identified in healthy controls. Transcript and genomic coordinates corresponds to human genome Build 37 (hg 19). The A region overlaps with exons 3–4, which corresponds to the UBL and RING0 domain of the Parkin protein. The B region overlaps exon 5, which corresponds to the RING0 domain of the Parkin protein. The C region overlaps with exons 6–7, which corresponds to the RING0 and RING1 domain of the Parkin protein

Fig. 2

Detection of CNVs at the PARK2 locus by genomic qPCR. a SYBR-based qPCR assays were performed to validate exonic CNVs at the PARK2 locus in the cases and the family members. Data is presented as mean ± SD. b Additional two ASD cases with CNV at exon 3 of the PARK2 locus were detected. c Copy number changes of five exons (exons 1 to 5) of the PARK2 gene were measured to determine the spanning of the CNV region in cases U2650 and U2890. EX exon. Data is presented as mean ± SD. d Pedigrees of probands with PARK2 exonic CNVs. Arrows indicate the proband in each family. N/A genomic DNA was not available, del deletion, dup duplication. Exons involved are determined by genomic qPCR

CNV detection in the replication cohort focused on exons in regions A, B, and C by using genomic qPCR with the same primer pairs used for validation. We detected two exonic CNVs (one deletion, one duplication, F patient = 0.66 %) at the A region carried by two ASD cases (Fig. 2b) while no exonic CNVs were detected in controls. The probability that the CNVs identified in the two cases might extend to adjacent exons was tested by using genomic qPCR with primer pairs specific to exons 1, 2, 4, and 5, respectively. The results showed that U2650 indeed had a deletion spanning exons 2–4 (Figs. 1 and 2c). The PARK2 transcript missing exons 2–4 is predicted to result in frameshift and lead to a nonsense mutation at codon 9 in the mutant mRNA. U2890 had a duplication overlapped with exons 2–3 (Figs. 1 and 2c). Taken together, the frequency of exonic CNVs at the PARK2 locus was significantly greater in ASD cases (6/636) than in controls (2/1394, P = 0.014, Additional file 1: Table S5). Of note, five probands revealed that the PARK2 CNVs were paternally inherited (Fig. 2a, b, d) except that the DNA sample was not available from the father of U2890. We could only confirm that the duplication was not inherited from the mother (Fig. 2b). In addition, we observed that the sister of U2650, who had the same PARK2 exonic deletion, did not demonstrate any autistic feature. In contrast, the father of U1984 (duplication) was clinically diagnosed with high-functioning autism (Fig. 2a, d).

PARK2 expression analysis

To assess how this exonic CNV affected gene function, we performed quantitative RT-PCR (qRT-PCR) to compare the mRNA expression level of PARK2 in individuals with and without exonic CNV. Family U1984 and Family U2650 consented to this experiment and were found to possess two different types of CNVs covering exon 3 and exon 4 which belonged to the A region at the PARK2 locus. We used two primer pairs specific to the CNV-affected regions (exons 3–4 and exons 4–5), and two primer pairs specific to the CNV-unaffected regions (exons 6–7 and exons 9–11) for the quantification of PARK2 mRNA expression, respectively. We observed a fold change of 0.61 for exons 4–5, 0.48 for exons 6–7, and 0.58 for exons 9–11 in the proband and the father of Family U1984 when compared with unaffected controls (P = 0.014, P = 0.026, and P = 0.01, respectively). In contrast, no difference in the expression level of exons 3–4 was detected (Fig. 3a).
Fig. 3

Expression analysis of PARK2. The expression level of PARK2 transcript was detected using four primer pairs specific to EX3-4, EX4-5, EX6-7, and EX9-11, respectively. Decreased expression level of specific PARK2 exons was observed in (a) case group of Family U1984 and (b) case group of Family U2650 (*P < 0.05, **P < 0.01). c Alternative splicing of PARK2 gene produces three known transcript variants (transcript variant 1: grey, transcript variant 2: blue, transcript variant 3: red) according to RefSeq Gene. Arrows on the top of the gene locus indicate the primer pairs used for expression detection. d The proposed genomic DNA rearrangement and PARK2 mutant transcript (purple) in the proband U1984 with duplication of EX3-4 on PARK2 based on the result of qRT-PCR. The frame was drawn in orange to represent the EX3-4 duplication. e The proposed PARK2 mutant transcript (green) in the proband U2650 with deletion of EX2-4 on PARK2 based on the result of qRT-PCR

We observed a fold change of 0.46 for exons 3–4 and 0.56 for exons 4–5 in the proband and deletion-carriers of Family U2650 when compared with those of unaffected controls (P = 0.014 and P = 0.004, respectively). However, no significant difference of the expression level of exons 6–7 or exons 9–11 between controls and deletion-carriers was found (Fig. 3b).

There were three transcript variants of the PARK2 gene according to the RefSeq Gene database (Fig. 3c). The exon-dependent change of PARK2 expression level in the probands and carriers of Family U1984 and Family U2650 implies that both the wild-type and mutant genomic copy of the PARK2 gene were expressed. Based on the qRT-PCR result, it is likely that the transcript variant 1 from the wild-type genomic copy (Fig. 3c) and mutant transcript consisting of exons 1–4 resulted from the mutant genomic copy (Fig. 3d) were expressed in the proband and the father of Family U1984. Likewise, the transcript variant 1 from the wild-type genomic copy (Fig. 3c) and mutant transcript missing exons 2–4 resulted from the mutant genomic copy (Fig. 3e) were suspected to be expressed in the individuals of Family U2650 with deletion of exons 2–4.

Clinical features of patients with PARK2 exonic CNVs

Pedigrees of these six families with male probands are illustrated in Fig. 2d. The age at recruitment (6–21 years old), clinical diagnosis, intelligence quotient (IQ) profiles (full-scale IQ, 83-117), subscores of the ADI-R and SRS, and WCST indexes of the five probands (except U2890) are summarized in Table 2. Based on the clinical assessment, all the parents of the six patients did not have ASD except that the father of U1984 had high-function autism (HFA) and the father of U1469 had autistic trait assessed by the autism-spectrum quotient (AQ) (Additional file 1: Table S6).
Table 2

Clinical features of male probands with PARK2 exonic CNV

 

U1469

U1290

U1859

U1984

U2650

U2890

Initial sample

335 probands

(Mean ± SD)

Replication sample

301 probands

(Mean ± SD)

Age (year) of diagnosis

6

2

8

7

8

Age (year) of recruitment

6

15

10

7

10

21

9.39 ± 4.04

10.66 ± 5.36

Clinical diagnosis

Autism

HFA

HFA

Autism

HFA

Autism

CNV type/region

Loss/exons 6–7

(C region)

Loss/exon 5

(B region)

Loss/exon 5

(B region)

Gain/exons 3–4

(A region)

Loss/exons 2–4

(A region)

Gain/exons 2–3

(A region)

  

Inheritance

Paternal

Paternal

Paternal

Paternal

Paternal

Unknown

  

Speech delay

N

Y

Y

Y

N

  

Other

Epilepsy

  

Autism Diagnostic Interview-Revised (ADI-R) (current/past)

        

 Qualitative abnormalities in reciprocal social interaction (cut-off = 10)

19/26

11/21

10/19

13/27

5/4

12.39 ± 5.76/20.43 ± 6.12

12.51 ± 5.69/20.77 ± 6.28

 Qualitative abnormalities in communication, verbal (cut-off = 8)

10/13

5/12

8/14

13/16

9/13

11.48 ± 3.83/14.75 ± 4.32

13.10 ± 4.59/15.87 ± 4.63

 Restricted, repetitive, stereotyped patterns of behaviors (cut-off = 3)

7/7

2/5

3/5

6/10

4/6

5.43 ± 2.48/6.95 ± 2.47

5.61 ± 2.46/7.29 ± 2.65

 Abnormality of development evident at or before 36 months (cut-off = 1)

2

5

2

4

1

3.44 ± 1.53

3.18 ± 1.63

Social Responsiveness Scale (SRS)

Raw (t score)

        

 Social communication (score 0–84)

42 (84.81)

42 (89.91)

34 (74.08)

49 (92.51)

17 (56.50)

37.28 ± 14.13

41.04 ± 15.07

 Stereotyped behaviors/interest (score 0–39)

24 (83.74)

24 (90.13)

17 (70.30)

27 (89.47)

10 (57.17)

18.88 ± 7.00

20.04 ± 7.42

 Social awareness (score 0–33)

24 (65.07)

28 (69.01)

23 (62.20)

21 (60.23)

16 (51.36)

21.70 ± 4.97

21.85 ± 5.45

 Social emotion (score 0–24)

16 (71.43)

15 (72.56)

15 (69.22)

14 (66.97)

7 (51.44)

11.45 ± 4.55

12.64 ± 4.76

 Total score (score 0–180)

106 (83.32)

109 (88.77)

89 (72.90)

111 (85.76)

50 (55.25)

89.24 ± 25.84

95.57 ± 28.56

Intelligence quotient (IQ)

        

 Verbal IQ (range)

117

122

107

84

121

95.08 ± 23.79 (44–148)

94.80 ± 23.79 (40–145)

 Performance IQ (range)

90

94

95

85

111

96.74 ± 21.04 (41–145)

94.96 ± 21.28 (40–139)

 Full–scale IQ (range)

105

109

102

83

117

94.85 ± 22.55 (40–148)

93.56 ± 23.14 (40–141)

Wisconsin Card Sorting Test (WCST) (%)

        

 Total errors

63 (4 %)

35 (21 %)

19 (84 %)

48 (14 %)

16 (92 %)

44.11 ± 26.61

39.75 ± 25.25

 Perseverative response

34 (14 %)

20 (21 %)

6 (96 %)

55 (2 %)

8 (88 %)

27.32 ± 25.29

25.95 ± 26.15

 Perseverative errors

30 (13 %)

19 (18 %)

6 (97 %)

43 (3 %)

8 (87 %)

23.51 ± 19.31

22.23 ± 19.95

 Nonperseverative errors

33 (4 %)

15 (32 %)

13 (53 %)

5 (92 %)

8 (82 %)

20.60 ± 15.71

17.60 ± 12.07

 Conceptual level responses

18 (4 %)

53 (18 %)

77 (82 %)

39 (16 %)

81 (91 %)

58.44 ± 23.96

59.52 ± 21.03

 Categories completed

2 (>16 %)

6 (>16 %)

6 (>16 %)

1 (>16 %)

6 (>16 %)

4.12 ± 2.03

4.39 ± 2.02

CNV copy number variation, ADI-R the ADI-R interviews revealed the 636 patients scored 20.7 ± 6.5 in the “qualitative abnormalities in reciprocal social interaction” (cut-off = 10), 15.2 ± 4.7 in the “qualitative abnormalities in communication, verbal” (cut-off = 8), and 7.0 ± 2.7 in the “restricted, repetitive, and stereotyped patterns of behaviors” (cut-off = 3), SRS the Chinese version of the Social Responsiveness Scale (60 items; score 0 (never true) - 3 (almost always true); total scores can range from 0 to 180) and the t score was generated by comparing to Taiwanese norm, HFA high function autism. WCST percentile ≤ 10 %: poor performance, percentile 11~90 %: normal range, percentile ≥ 91 %: great performance

Both U1984 and U2650 were found to have CNVs at the A region of PARK2 with different exonic CNV patterns (duplication/deletion). U1984 was born in a family with unrelated parents and had an unaffected typically developing younger brother. He presented speech delay (two words and simple sentence at age 4), stereotyped and socially inappropriate speech, abnormal social reciprocity, and restricted/repetitive behaviors and interests. He demonstrated severe autistic symptoms compared to U2650 in a wide range of autistic features at his age of 4–5 years old and current status (Table 2). He suffered from the first attack of absence seizure at his age of 2.5 years old but no anti-epileptic drug was used. U1984 had a relatively lower IQ profile (Full-IQ = 83) than the other four probands, and his performance of WCST showed increased perseverative response and errors, suggesting an impaired cognitive flexibility.

U2650 (deletion in PARK2), diagnosed as HFA, showed no speech delay and less severe autistic symptoms assessed by the ADI-R and SRS compared to the other probands. His key features were socially inappropriate communication and interactions, a lack of non-verbal communication (e.g., eye contact, gesture, or distal index pointing), and stereotyped pattern of interests, verbal rituals, and schedules (Table 2). He demonstrated above average IQ profiles (Full-IQ = 117) and did not have impaired WCST performance. Although his sister carries the same deletion in PARK2, the clinical assessment and parental reports revealed her as a typically developing child without any autistic symptom.

U1469, who carried an exonic deletion spanning exons 6–7 of PARK2, showed abnormal social reciprocity and communication, neither sharing nor comforting, sameness in a wide range of behaviors, and unusual sensory interests, which had been clearly noted before 3 years old. Despite IQ profiles within the normal range, he demonstrated impaired cognitive flexibility as assessed by the WCST (Table 2). His PARK2 deletion was inherited from his father, who showed some autistic trait such as restricted interests, social inflexibility, and concrete thought based on clinical assessment.

Both U1290 and U1859, diagnosed with HFA, had exonic deletions spanning exon 5 of PARK2 (Table 2). U1290 exhibited speech delay and started to combine two words to make simple sentences until age 4; U1859 was observed to have speech delay. They both had difficulty in offering comfort to other people, engaging reciprocal social interactions, developing peer relationships, and imitating behaviors/action. The cognitive assessments of these two probands did not reveal any abnormal results, but U1859 revealed better WCST performance than U1290.

In this study, we focused on the case-specific CNVs rather than rare CNVs (<1 % frequency in total samples). With this approach, we have sufficient power to catch variants that exist only in ASD cases without losing any important CNVs that have >1 % frequency. For example, we found that the CNVs on chromosome 3q22.1 and 9q13 were presented at more than 1 % of frequency in the total samples, but indeed were contributed only from the cases (Table 1). Among the candidate genes overlapped with case-specific CNV loci, we focused on PARK2, which has been known to be associated with ASD [15], other neuropsychiatric disorders [13, 14, 16], and neuronal functions in Caucasian population [2528]. With two independent sets of case-control cohorts, we demonstrated that the frequency of CNVs affecting PARK2 gene was significantly higher in individuals with ASD compared to controls (0.94 vs. 0.14 %, P = 0.014). Our findings strongly suggest that CNVs at the PARK2 locus contribute to the susceptibility of ASD in the Han Chinese population residing in Taiwan. Of note, in the present study, there were 12 people who carried PARK2 CNVs from six families, and seven of them were diagnosed with ASD, and the PARK2 CNVs were often transmitted by unaffected parents. The study of Icelandic population by Huttenlocher and her colleagues demonstrated that the frequency of heterozygous PARK2 CNVs was significantly higher in patients with Parkinson’s disease (PD) compared to controls (OR = 1.69, P = 0.03) [29]. They concluded that heterozygous carriers for exonic CNVs in PARK2 were at an increased risk of developing PD. On the other hand, their results also clearly demonstrated that there was a significant proportion of individuals who carried heterozygous PARK2 CNV who did not develop PD after age 65. Therefore, based on their results, the penetrance for PD from heterozygous CNVs in PARK2 would not be high. In this report, the six indexed ASD cases, one affected father, and the five unaffected carriers were all heterozygote of PARK2 CNVs. Therefore, we speculate that the penetrance for ASD from heterozygous PARK2 CNV was not high, either.

Our result that PARK2 is strongly suspected as a candidate gene for ASD is in line with Glessner’s observation [15]. However, the enriched CNVs in their study were located at the intronic region and might not directly influence the expression or function of the gene [15]. Moreover, a comprehensive study of PARK2 showed that CNVs involving PARK2 were identified in 1 % of control subjects, and CNVs involving exons 2–4 were well-tolerated while exons 5–12 were not. Kay and colleagues suggested that the mutations affecting exons 5–12, the coding region for highly conserved function domains of Parkin, might be more deleterious [30]. This suggestion may explain our findings on the clinical features of four probands: U1469 (exons 6–7) had more severe autistic symptoms than U1290 and U1859 (exon 5), and U2650 (exons 2–4) had less severe autistic symptoms than other probands.

The PARK2 transcript missing exons 2–4 is predicted to result in a frameshift and lead to a nonsense mutation at codon 9 in the mutant mRNA. Similar to the prediction, we observed that the mRNA expression levels in U2650 and carriers with EX2-4 deletion were changed in an exon-dependent manner: decreased by half in the CNV-affected exons but was not affected in the CNV-unaffected exons, suggesting that a mutant PARK2 transcript without EX2-4 is generated (Fig. 3e). However, surprisingly, nonsense-mediated decay did not occur with this transcript. We speculate that the mutant transcript would be translated into a non-functional protein, and the individual carrying this mutation has half dose of functional PARK2 proteins. However, U2650 was one of the less severe autistic symptoms of patients with PARK2 exonic CNV in this study, supporting that intragenic deletion involving exons 2–4 might be less pathogenic for autistic symptoms.

On the other hand, U1984 who possessed a duplication-type CNV encompassing exons 3–4 manifested more severe autistic symptoms and worse cognitive function than other patients with deletion-type CNVs. The distinct phenotypes might be due to the different dosages of CNV (duplication/deletion). Interestingly, the duplication was partially overlapped with the findings from Scheuerle et al. [17]. They reported a male who had a duplication encompassing exon 2 on PARK2 and revealed cognitive impairment and global developmental delay with particular problems on social and language skills [17]. Later, Marinai and colleagues described similar situation, and their observations also supported the idea that duplication of the PARK2 gene possibly plays a role in the pathology of developmental anomalies [31]. Those probands with duplications from Scheuerle et al’s and Marinai et al’s studies seem to have similar clinical features with U1984 who suffered from language delay and epilepsy. Intriguingly, we observed down-regulation of EX4-5, EX6-7, and EX9-11 but normal expression of EX3-4 on the mRNA level in proband U1984 and the carrier with duplication of EX3-4 on PARK2 in the family. Based on the expression analysis, we speculate that the copy number gain may lead to a splicing error; hence, a shorter transcript lacks most of the 3′ end of the PARK2 mRNA (Fig. 3d). Whether the mutant transcript would interfere with the normal PARK2 transcript (Fig. 3c) is not clear. Nevertheless, the observation that U1984 had the most severe ASD and cognitive impairment among the probands with CNVs on PARK2 might imply that duplication of PARK2 EX3-4 has effect beyond decreasing PARK2 protein. These observations warrant further investigations of pathogenic mechanism of PARK2 CNVs.

The PARK2 gene encodes Parkin, a RING-between-RING E3 ubiquitin ligase functioning in the covalent attachment of ubiquitin to specific substrates for proteasomal degradation [32]. The structure of human Parkin ligase has been reported in exquisite detail [3335]. Parkin is structurally tight packed by two hydrophobic interactions, which keep Parkin in an auto-inhibited conformation. A study showed that mutations (M192A, F463A, and A398T) at the RING0-RING2 domain and linker helix could disrupt the interface and lead to autoubiquitination of PARK2 (the “opening” structure) in cell [27]. The deletion encompassing exon 5 of the PARK2 gene in U1290 and U1859 is predicted to result in in-frame deletion which leads to losing a part of RING0 domain. This may lead to a conformational change of Parkin protein and activation of the autoubiquitination. The deletion encompassing exons 6–7 of the PARK2 gene in U1469 is predicted to cause the Glu207Leu amino acid change and lead to nonsense mutations at the 213th codon of the mutant mRNA (Additional file 1: Figure S3). We speculate that this intragenic deletion might largely influence the biological functions of Parkin owing to truncated protein lacking the C-terminal part. However, we were unable to obtain the RNA sample from the probands with deletions comprising exon 5 or exons 6–7 for gene expression analysis. Further studies to investigate how these deletions affect Parkin at the transcript level, protein level, and function level are needed to reveal PARK2 CNV-mediated ASD pathogenesis.

Literature documents that Parkin plays a fundamental role in mitochondrial functions. The PINK1-Parkin pathway is one of well-studied pathways of mitophagy. Mutations in PINK1 and PARK2 are associated with neurodegeneration in Parkinson Disease [13, 25] and are hypothesized to impair the protein function and hence result in insufficient mitochondrial clearance and subsequent aggregation. In addition, a recent study has also shown that loss of Parkin function suppressed mitochondrial biogenesis through accumulation of Parkin-interacting substrate (PARIS), a transcriptional repressor of PGC-1a, which stimulates mitochondrial biogenesis as an activator [26]. Taken together, these evidences strongly suggest that Parkin with a loss-of-function mutation may lead to abnormal mitochondrial biogenesis and clearance, which is considered to link to the pathology of ASD [36]. In addition, Parkin protein is abundantly expressed in the human brain, including the frontal lobe cortex, substantia nigra, putamen, and locus coeruleus [28]. Therefore, with the observations reported in this study, we suspect that the ASD-associated PARK2 CNV might contribute to the pathogenesis of ASD through affecting mitochondria in particular brain region (e.g., frontal lobe) in a proportion of children.

Conclusions

In summary, our study indicated that PARK2 could be a pathogenic gene associated with ASD in the Han Chinese population. With limited samples, we also observed that exonic duplication might result in a more severe interference of PARK2 expression and the clinical feature than deletion at the A region (exons 2–4) of the PARK2 locus. The intriguing results of this work warrant further study on characterizing the functional impact of various exonic CNVs on the PARK2 gene and its role in mitochondria malfunction in the brain of patients with ASD.

Abbreviations

aCGH: 

array-based comparative genomic hybridization

ADHD: 

attention-deficit/hyperactivity disorder

ADI-R: 

Autism Diagnostic Interview-Revised

AQ: 

autism-spectrum quotient

ASD: 

autism spectrum disorders

cDNA: 

complementary deoxyribonucleic acid

CNV: 

copy number variations

DNA: 

deoxyribonucleic acid

DSM-IV: 

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition

EX: 

exon

GWAS: 

genome-wide association study

HFA: 

high-function autism

IQ: 

intelligence quotients

mRNA: 

messenger ribonucleic acid

NCGM: 

National Center for Genome Medicine

PARIS: 

Parkin-interacting substrate

PCR: 

polymerase chain reaction

PD: 

Parkinson disease

qRT-PCR: 

quantitative reverse transcriptase polymerase chain reaction

RNA: 

ribonucleic acid

SNP: 

single nucleotide polymorphism

SRS: 

Social Responsiveness Scale

WCST: 

Wisconsin Card Sorting Test

WISC-III: 

Weschler Intelligence Scale for Children-3rd edition

Declarations

Acknowledgements

We thank the National Center for Genome Medicine of the National Core Facility Program for Biotechnology, Minister of Science and Technology, for the technical support. We thank the children and their families for their participation and support to this study.

This work was supported by grants from the National Science Council (NSC96-3112-B-002-033, NSC97-3112-B-002-009, NSC98-3112-B-002-004, and NSC 99-3112-B-002-036), the Ministry of Science and Technology, Taiwan (MOST 103-2314-B-002-055-MY3), National Taiwan University (AIM for Top University Excellent Research Project: 101R892103, 102R892103, 103R892103), and National Taiwan University Hospital (NTUH104-N2933).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Psychiatry, National Taiwan University Hospital and College of Medicine
(2)
Graduate Institute of Brain Sciences, National Yang-Ming University
(3)
Institute of Biomedical Sciences, Academia Sinica
(4)
Section on Molecular Neurobiology, National Institute of Mental Health, National Institutes of Health
(5)
Department of Child Psychiatry, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine
(6)
Department of Child Psychiatry, Chang Gung Memorial Hospital, Chang Gung University College of Medicine

References

  1. Gmitrowicz A, Kucharska A. [Developmental disorders in the fourth edition of the American classification: diagnostic and statistical manual of mental disorders (DSM IV—optional book)]. Psychiatr Pol. 1994;28:509–21.PubMedGoogle Scholar
  2. Kim YS, Leventhal BL, Koh YJ, Fombonne E, Laska E, Lim EC, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry. 2011;168:904–12.View ArticlePubMedGoogle Scholar
  3. Alkan C, Coe BP, Eichler EE. Genome structural variation discovery and genotyping. Nat Rev Genet. 2011;12:363–76.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. Nature. 2006;444:444–54.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Shishido E, Aleksic B, Ozaki N. Copy-number variation in the pathogenesis of autism spectrum disorder. Psychiatry Clin Neurosci. 2014;68:85–95.View ArticlePubMedGoogle Scholar
  6. Miles JH, McCathren RB, Stichter J, Shinawi M. Autism Spectrum Disorders. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews(R). Seattle (WA): University of Washington, Seattle; 1993-2016. http://www.ncbi.nlm.nih.gov/books/NBK1442/.
  7. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, et al. Strong association of de novo copy number mutations with autism. Science. 2007;316:445–9.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466:368–72.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, Moreno-De-Luca D, et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron. 2011;70:863–85.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet. 2003;34:27–9.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007;39:25–7.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Dykens EM, Sutcliffe JS, Levitt P. Autism and 15q11-q13 disorders: behavioral, genetic, and pathophysiological issues. Ment Retard Dev Disabil Res Rev. 2004;10:284–91.View ArticlePubMedGoogle Scholar
  13. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605–8.View ArticlePubMedGoogle Scholar
  14. Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet. 2008;40:880–5.View ArticlePubMedGoogle Scholar
  15. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature. 2009;459:569–73.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Jarick I, Volckmar AL, Putter C, Pechlivanis S, Nguyen TT, Dauvermann MR, et al. Genome-wide analysis of rare copy number variations reveals PARK2 as a candidate gene for attention-deficit/hyperactivity disorder. Mol Psychiatry. 2014;19:115–21.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Scheuerle A, Wilson K. PARK2 copy number aberrations in two children presenting with autism spectrum disorder: further support of an association and possible evidence for a new microdeletion/microduplication syndrome. Am J Med Genet B Neuropsychiatr Genet. 2011;156B:413–20.View ArticlePubMedGoogle Scholar
  18. Gau SS, Liu LT, Wu YY, Chiu YN, Tsai WC. Psychometric properties of the Chinese version of the social responsiveness scale. Res Autism Spectr Disord. 2013;7:349–60.View ArticleGoogle Scholar
  19. Liao HM, Gau SS, Tsai WC, Fang JS, Su YC, Chou MC, et al. Chromosomal abnormalities in patients with autism spectrum disorders from Taiwan. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:734–41. doi:10.1002/ajmg.b.32153.View ArticlePubMedGoogle Scholar
  20. Pan WH, Fann CS, Wu JY, Hung YT, Ho MS, Tai TH, et al. Han Chinese cell and genome bank in Taiwan: purpose, design and ethical considerations. Hum Hered. 2006;61:27–30.View ArticlePubMedGoogle Scholar
  21. Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. Curr Opin Genet Dev. 2012;22:229–37.View ArticlePubMedGoogle Scholar
  22. Marshall CR, Scherer SW. Detection and characterization of copy number variation in autism spectrum disorder. Methods Mol Biol. 2012;838:115–35.View ArticlePubMedGoogle Scholar
  23. Menashe I, Larsen EC, Banerjee-Basu S. Prioritization of copy number variation loci associated with autism from AutDB—an integrative multi-study genetic database. PLoS One. 2013;8, e66707.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Sener EF. Association of copy number variations in autism spectrum disorders: a systematic review. Chinese J Biol. 2014;2014:2014.View ArticleGoogle Scholar
  25. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012;31:3038–62.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Batlevi Y, La Spada AR. Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging. Neurobiol Dis. 2011;43:46–51.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Huynh DP, Scoles DR, Ho TH, Del Bigio MR, Pulst SM. Parkin is associated with actin filaments in neuronal and nonneural cells. Ann Neurol. 2000;48:737–44.View ArticlePubMedGoogle Scholar
  28. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson’s disease. Cell. 2011;144:689–702.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Huttenlocher J, Stefansson H, Steinberg S, Helgadottir HT, Sveinbjornsdottir S, Riess O, et al. Heterozygote carriers for CNVs in PARK2 are at increased risk of Parkinson’s disease. Hum Mol Genet. 2015;24:5637–43.View ArticlePubMedGoogle Scholar
  30. Kay DM, Stevens CF, Hamza TH, Montimurro JS, Zabetian CP, Factor SA, et al. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology. 2010;75:1189–94.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Mariani M, Crosti F, Redaelli S, Fossati C, Piras R, Biondi A, et al. Partial duplication of the PARK2 gene in a child with developmental delay and her normal mother: a second report. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:485–6.View ArticlePubMedGoogle Scholar
  32. Riley BE, Lougheed JC, Callaway K, Velasquez M, Brecht E, Nguyen L, et al. Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat Commun. 2013;4:1982.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Wauer T, Komander D. Structure of the human Parkin ligase domain in an autoinhibited state. EMBO J. 2013;32:2099–112.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Hristova VA, Beasley SA, Rylett RJ, Shaw GS. Identification of a novel Zn2 + -binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase parkin. J Biol Chem. 2009;284:14978–86.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Anitha A, Nakamura K, Thanseem I, Yamada K, Iwayama Y, Toyota T, et al. Brain region-specific altered expression and association of mitochondria-related genes in autism. Mol Autism. 2012;3:12.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Shimura H, Hattori N, Kubo S, Yoshikawa M, Kitada T, Matsumine H, et al. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol. 1999;45:668–72.View ArticlePubMedGoogle Scholar

Copyright

© Yin et al. 2016

Advertisement